Literature DB >> 19222374

Lipoprotein(a) level and its association with tumor stage in male patients with primary lung cancer.

Hai-hua Yang1, Xiao-feng Chen, Wei Hu, Dong-qing Lv, Wei-jun Ding, Li-jiang Tang, Jian-jun Jiang, Min-hua Ye.   

Abstract

BACKGROUND: Recently, attention has been focused on the effect of lipoprotein(a) [Lp(a)] on tumors because of its possible role in development of tumor angiogenesis. The aim of this study was to investigate Lp(a) serum levels in patients with lung cancer and its association with the stages of disease.
METHODS: Fasting venous blood samples were collected from 418 untreated male patients with stages I-IV lung carcinoma and were analyzed for Lp(a). The results were compared with the data from 65 healthy male controls.
RESULTS: Lp(a) levels were elevated (median 157 mg/L, range 16-1497 mg/L) in patients with lung carcinoma compared to control subjects (median 110 mg/L, range 35-706 mg/L) (p=0.004). Subgroup analysis showed that patients with stages II-IV disease had significantly higher Lp(a) concentrations than did healthy controls (p-0.05). There was an independently positive correlation between tumor stage and Lp(a) levels among patients with stages I-III (r=0.162, p=0.006). However, there was a decrease in Lp(a) in stage IV compared to stage III patients (p=0.03).
CONCLUSIONS: There is a significant association between Lp(a) and the presence and stage of lung cancer. Additional investigations with a larger number of lung cancer patients are needed to confirm these findings.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19222374     DOI: 10.1515/CCLM.2009.094

Source DB:  PubMed          Journal:  Clin Chem Lab Med        ISSN: 1434-6621            Impact factor:   3.694


  6 in total

1.  Low lipoprotein(a) concentration is associated with cancer and all-cause deaths: a population-based cohort study (the JMS cohort study).

Authors:  Motoji Sawabe; Noriko Tanaka; Makiko Naka Mieno; Shizukiyo Ishikawa; Kazunori Kayaba; Ken-ichi Nakahara; Satoru Matsushita
Journal:  PLoS One       Date:  2012-04-02       Impact factor: 3.240

2.  Lipoprotein(a) and its role in inflammation, atherosclerosis and malignancies.

Authors:  Evelyn Orsó; Gerd Schmitz
Journal:  Clin Res Cardiol Suppl       Date:  2017-03

Review 3.  Advances in urinary biomarker discovery in urological research.

Authors:  Jayoung Kim; Won Tae Kim; Wun-Jae Kim
Journal:  Investig Clin Urol       Date:  2019-12-31

4.  Apolipoproteins as Differentiating and Predictive Markers for Assessing Clinical Outcomes in Patients with Small Cell Lung Cancer.

Authors:  Jian Shi; Huichai Yang; Xiaoyang Duan; Lihua Li; Lulu Sun; Qian Li; Junjun Zhang
Journal:  Yonsei Med J       Date:  2016-05       Impact factor: 2.759

5.  High Lipoprotein(a) Level Is Independently Associated with Adverse Clinicopathological Features in Patients with Prostate Cancer.

Authors:  Fang-Ming Wang; Yan Zhang
Journal:  Dis Markers       Date:  2019-11-22       Impact factor: 3.434

Review 6.  Proteomics for Early Detection of Non-Muscle-Invasive Bladder Cancer: Clinically Useful Urine Protein Biomarkers.

Authors:  Jae-Hak Ahn; Chan-Koo Kang; Eun-Mee Kim; Ah-Ram Kim; Aram Kim
Journal:  Life (Basel)       Date:  2022-03-09
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.